• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base

    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University

  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base

    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+

      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University

Archive for April, 2014

Biomedical Networking Event, 3rd June, Manchester Science Park

Funding opportunities for SME and academic collaborations

09.30 to 13.30 on Tuesday 3rd June 2014

Greenheys Building, Manchester Science Park, Manchester, M15 6JJ

Open to SMEs and academics, the event will highlight funding opportunities available to support collaborations that drive innovation in the biomedical sector. Academic-SME partnering has the capacity to sustain and generate high value jobs and revenue and enhance economic and social impact of research in the UK and Europe, driving innovation, and nurturing talent in a challenging economic climate. This event will help you to realise a successful partnership by facilitating access to funding and contacts.

Join us to:

•             Learn about funding opportunities for SME and academic partnerships

•             Receive information and contacts to facilitate future interactions

•             Network with funding experts, SME and academics in the biomedical sector

The morning will start with a series of short presentations which will introduce the benefits, best practice and key challenges of SME-academic partnerships in the biomedical sector and highlight specific funding opportunities for collaborations. This will be followed by an exhibition and networking session that will provide opportunity to meet funding experts, gain further information and establish contacts for future collaborations.

Click here to reserve your place: http://universityofmanchester.gtml2.com/universityofmanchesterlz//EventMgr_ShowEvent1.aspx?eID=14

For more information on biomedical business engagement at the University of Manchester: www.mhs.manchester.ac.uk/business

University of Manchester provides a unique underwater monitoring system to the nuclear industry

AVEXIS2Funding has been secured by The University of Manchester and a consortium of partners for the design, development and commercialisation of a unique low-cost, scalable mobile sensor system which can operate, survey and analyse surroundings individually or as part of a swarm in bodies of water. Commercialisation will be undertaken by UMIP, the University’s technology transfer arm.

The funding will enable the development of the University’s Aqua Vehicle Explorer for In-situ Sensing (AVEXIS) technology in two parallel work streams.

The first development project (miniROV) has been driven by Sellafield’s requirement to find a device which could access and remotely assess a storage compartment on the Sellafield site.

The tethered mini-ROV will be equipped with a video camera and will scan and assess the pond’s underwater environment and provide detailed real-time data which will be transmitted back to researchers.

The project has been funded by a consortium which includes The University of Manchester, through its UMIP Proof-of-Principle Fund, the EPSRC (Engineering and Physical Sciences Research Council) IAA Exploitation Secondment Fund and Sellafield Ltd. Forth Engineering will act as a subcontractor for the majority of the mechanical work and deployment of the vehicle on Sellafield’s site. The final output of the project will be a CE marked and fully Sellafield-compliant device.

Commenting on the Sellafield project Mark Dowson, Business and Technology Manager Sellafield Ltd Technical Directorate, said: “This is a great example of industry turning to the University to help find better solutions and new technology to improve the delivery of our Decommissioning mission. This storage compartment is difficult to access for any extended period of time and sealed, so it is desirable to employ a remote device to carry out this survey. This particular mini-ROV is the perfect device as it can fit through a restricted access port, is highly manoeuvrable, and it can scan the environment and send back data for analysis.”

The second project is to further develop the core AVEXIS technology. UMIP have secured a separate funding package from partners including the University and its Dalton Nuclear Institute, Innovus and Forth Engineering. This funding will enable the development and deployment of two AVEXIS vehicles which are able to communicate with each other and a central base station, taking sensor measurements as they autonomously navigate an uncluttered environment. These untethered vehicles will be tested in Forth Engineering’s ponds.

Dr Simon Watson of the School of Electrical & Electronic Engineering at The University of Manchester commented: “These projects are a great example of how research can be progressed from the University into the real-world and provide benefits to both industry and academia.”

Beyond the successful development of the core technology the vision is to manufacture multiple devices, with the ability to carry different sensor payloads, providing greater functionality and with the swarming capability allowing collaboration to improve the resolution of both sensing and positioning.

Both projects are a milestone for the nuclear industry and are substantial for Cumbria. The technology is also seeking applications in the Oil & Gas and Water Sectors.


Innovus final proof






Forth_logo_black_background  UMIP logo

UoMLimited space 300DPI jpegweb

New University of Manchester spin-out, Spectromics Limited, set to develop novel technology for effective use of antibiotics and other antimicrobial therapeutics

Manchester, UK  07/04/2014: University of Manchester spin-out, Spectromics Limited, is set to develop novel technology that will help guide the effective use of antibiotics and other antimicrobial therapeutics.

The formation of Spectromics is the result of three years of research by Professor Roy Goodacre of the Institute of Biotechnology and School of Chemistry at The University of Manchester, and Dr Mathew Upton, School of Biomedical and Healthcare Sciences, Plymouth University Peninsula Schools of Medicine and Dentistry, formerly at the School of Inflammation and Repair at The University of Manchester. Both are Directors of the company.

The technology, relating to rapid diagnostics for antimicrobial susceptibility testing, will allow doctors to determine the most effective drug to be prescribed for each patient, bringing a personalised medicine approach to the widespread use of antibiotics.

Growing resistance to antimicrobials is a global threat to the successful treatment of bacterial infections. This is a problem that is recognised by all of the major nations; the UK Chief Medical Officer stated that it is one of the three biggest threats to human health and it featured at last year’s G8 conference as a threat ranked alongside terrorism. Resistance to antibiotics is exacerbated by the current practice of issuing “best guess” prescriptions without knowing whether the patient actually has a bacterial infection, and whether that particular infection may be resistant to the drug being prescribed.

To run tests today to determine whether a drug is required and which is most effective takes days in a microbiology lab. The Spectromics technology will allow a doctor to run a 10 minute test which will indicate if an antibiotic is required, and if so, which one. The test will comprise of a small instrument and a cartridge into which the sample is added.

Over the next three years Spectromics will develop the commercial system for the first application. This will be for urinary tract infection which is the most prevalent bacterial infection affecting human health. Following this, other test specific cartridges for other clinical applications will follow.

Neil Butler, CEO of Spectromics commented: “I have been the CEO from formation of two other companies in the past, Vivacta and Oxford Biosensors, and worked in Point-of-Care diagnostics for fifteen years. What really excites me about Spectromics is the compelling need for a diagnostic that guides antibiotic treatment at the point-of-prescription. This technology is very differentiated as nothing else comes close to our test turnaround time. We are planning to raise significant investment, so that we can build the organisation rapidly, which in turn will bring the commercial system to market ASAP. This product was needed yesterday and we are going to make this technology the answer to the global call for a solution to antimicrobial stewardship.”

Stephen France of UMIP, the University of Manchester’s agent for Intellectual Property commercialisation, added: “The lack of new antibiotics, that has caused a 30 year discovery void, is alarming as our established drugs have a growing resistance making them ineffective in treating infections. The worry is that what have in the past been easily treated bacterial infections could in future be untreatable and life threatening. There are solutions to this problem: new antibiotics, and better stewardship of the ones we have, and we believe that both solutions are required for an effective remedy of the problem. When we saw the speed of this technology we knew it was a winner and this why we didn’t hesitate to build a business to exploit it fully.”

Contact Spectromics: email neil@meddx.co.uk